Cromisol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cromisol

What is Cromisol?

Cromisol is a pharmaceutical formulation containing cromoglicic acid, often referred to as sodium cromoglicate. It belongs to a class of medications known as mast cell stabilizers. Unlike medications designed to reverse an allergic reaction once it has begun, Cromisol is primarily used as a preventive treatment to manage and reduce the frequency of allergic symptoms.

Mechanism of Action

The active ingredient in Cromisol works by stabilizing specific immune cells called mast cells. Mast cells are found throughout the body, particularly in areas exposed to the environment, such as the eyes, nose, and lungs. When a person with allergies is exposed to a trigger—such as pollen, dust mites, or pet dander—these mast cells typically release inflammatory substances, including histamine.

By stabilizing the membrane of the mast cell, Cromisol prevents the release of these inflammatory mediators. Because it acts on the source of the allergic response rather than blocking receptors after the response has started, it is most effective when used consistently and before exposure to known allergens.

Therapeutic Applications

Cromisol is utilized across different formats to address localized allergic conditions. Its applications generally include:

  • Ophthalmic Care: Used as eye drops to manage allergic conjunctivitis. It helps reduce redness, itching, and swelling of the eyes caused by seasonal or perennial allergens.
  • Nasal Care: Used as a nasal spray to prevent allergic rhinitis (hay fever), addressing symptoms such as sneezing, congestion, and an itchy or runny nose.
  • Respiratory Management: In some formulations, it is used via inhalation to prevent exercise-induced bronchospasm or to manage chronic asthma by reducing airway inflammation over time.

Because Cromisol is poorly absorbed into the systemic bloodstream, its effects are largely confined to the area of application, which generally results in a localized therapeutic profile.

Regulatory References

  1. DailyMed - FDA Information
  2. NIH Mast Cell Stabilizer Definition

What side effects are possible with Cromisol?

Possible Side Effects and Safety Information

The safety profile of Cromisol (Sodium Cromoglycate) is formally categorized by regulatory agencies based on frequency and the body system affected. Adverse effects are generally classified as having a low incidence, with many reactions identified through post-marketing experience.


Adverse Reactions by Frequency and System

Official regulatory documents classify certain effects based on the route of administration:

  • Common Reactions: Headache and Diarrhea are reported as common in clinical studies of the oral solution. For the ophthalmic solution, the most frequently reported reaction is transient ocular stinging or burning upon instillation.
  • Rare Reactions: Less common events include pruritus, nausea, myalgia (muscle aches), abdominal pain, and rash. Critical reactions such as Anaphylaxis and Laryngeal edema are reported rarely.

Adverse effects are grouped into System-Organ Classes, including Gastrointestinal Disorders (e.g., vomiting, flatulence), Nervous System Disorders (e.g., dizziness), Musculoskeletal and Connective Tissue Disorders (e.g., joint pain), and Respiratory Disorders (e.g., cough, throat irritation) for inhaled or nasal forms.


Specific Safety Considerations

Serious Adverse Reactions include severe allergic manifestations like Anaphylaxis, Laryngeal edema, and Severe Bronchospasm. The medicine is contraindicated in patients with a known hypersensitivity to the active substance or any excipients.

Population-Specific Notes: Caution is required in older adults and patients with hepatic or renal impairment due to the potential for increased drug effect. The safety and efficacy of the oral solution are not established in children under two years of age. For ophthalmic use, patients are advised to refrain from wearing soft contact lenses during treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory documentation for Cromisol (Sodium Cromoglycate) consistently defines a specific overdose profile characterized by an extremely low risk of toxicity. Official labeling confirms that the substance has an extremely low order of local or systemic toxicity.

Documented Overdose Profile

Regulatory sources state that there is no clinical syndrome associated with an overdosage and no toxic effect has been reported in humans. Consequently, no specific symptoms or severe physiological effects are documented in the overdose profile. This finding is consistent across multiple government health authorities. No specific antidote is officially known or described for managing overdosage.

Required Emergency Actions and Management

Despite the low-toxicity profile, official guidance mandates immediate action in the event of accidental ingestion or suspected overdosage. This information must be strictly followed:

  • Urgent Contact: You must seek professional assistance or contact a Poison Control Center immediately. This is the mandatory emergency action stated in regulatory labeling.
  • Official Management: The required procedural steps are limited. Management should focus on medical observation and the provision of symptomatic treatment.
  • Local Exposure: For cases involving excessive local administration (e.g., ophthalmic solution), the documented procedure may include copiously washing the affected area with sterile physiologic serum.

Therapeutic Uses of Cromisol

Cromisol is a prophylactic therapy applied in conditions involving certain distressing symptoms. This medicine is generally used for managing allergic conjunctivitis, allergic rhinitis, mild to moderate chronic asthma, and Systemic Mastocytosis.

Managing Allergic Symptoms of the Eyes and Nose

Cromisol is commonly used across domains where additional symptomatic support is needed for seasonal and perennial allergic reactions affecting the eye and nasal lining. This generally helps address symptom clusters that may become intense or disruptive, such as persistent ocular itching, excessive tearing, sneezing, and a persistently runny or itchy nose. The use may contribute to improved comfort during periods of heightened symptoms and supports patients during episodes of symptom fluctuations.

“The intent is to support the patient during difficult symptomatic periods and assist with easing distress caused by recurrent allergic and systemic manifestations.”

Supporting Systemic Management and Prophylaxis

This medicine is relevant in contexts involving heightened systemic burden, specifically for managing the diverse symptoms of Systemic Mastocytosis. It also plays a role in managing airway instability, such as the prevention of Exercise-Induced Bronchoconstriction (EIB). It helps address symptom clusters that create noticeable physiological strain, including gastrointestinal distress and cutaneous reactions like flushing. It may assist with maintaining functional stability and contributes to easing the overall symptom load during difficult episodes.


Quick Fact: Relevant for Ocular Itching

Regulatory References

  1. NIH National Library of Medicine overview

Eligibility and Restrictions for Use

Eligibility Scope

Field Official Regulatory Statement
Populations for whom use is contraindicated: Patients who have demonstrated hypersensitivity to the active substance or any of the excipients.
Age-related eligibility rules: Approved for patients two (2) years of age and older. Use in infants and children under two is generally reserved for severe disease where the benefits clearly outweigh the risks. Dose selection for older adults should be cautious due to the higher probability of reduced organ function.
Condition-specific eligibility rules: Dosage adjustment or special consideration is required for patients with impaired renal or hepatic function, as the drug is primarily eliminated via these systems.
Pregnancy and lactation eligibility status: Pregnancy Category B. Use during pregnancy is permitted only if clearly needed. It is not known if the drug is excreted in human milk; caution is advised when administering to a nursing woman.

Eligibility-Related Restrictions

Official labeling defines non-eligibility through a strict hypersensitivity contraindication. For most other populations, the profile outlines necessary constraints. This includes mandatory dosage review for patients with reduced liver or kidney function and reserving use in infants younger than two years for only severe, essential cases, reflecting limitations in established safety data for those groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cromisol (Sodium Cromoglycate) has a low potential for widespread systemic drug–drug interactions. Regulatory documents confirm that no clinically significant pharmacokinetic (CYP-mediated) interactions are known because the medicine is poorly absorbed and excreted largely unchanged in the urine and bile.

Co-Administration and Administration Restrictions

The restrictions documented in official labeling primarily concern administration conditions and physical compatibility.

Restriction Type Specific Requirement/Condition
Physical Incompatibility The inhalation solution must not be mixed with Ipratropium Inhalation Solutions in a nebulizer due to the risk of precipitation.
Timing Rule (Oral Solution) The oral solution must be taken 30 minutes prior to meals and at bedtime.
Mixing Restriction (Oral Solution) The oral solution/powder must not be mixed with milk, fruit juice, or food.

Population-Dependent Considerations

Due to the medicine's elimination via the liver and kidneys, a specific caution is noted in the regulatory labels:

A decrease in dosage should be considered for patients with impaired renal function or impaired hepatic function.

Mechanism of Action

Cromisol operates as a mast cell stabilizer by modulating cellular activity at the site of administration. Its primary action is the inhibition of mast cell degranulation, a process central to the release of inflammatory mediators. This mechanism involves engaging components that regulate the necessary influx of calcium ions required to trigger the exocytosis of granules.

Stabilizing the cell membrane prevents the rapid discharge of pre-formed pro-inflammatory substances, including histamine and leukotrienes. This disruption of the early molecular signaling cascade results in a quantifiable reduction in excessive mediator activity.

Furthermore, evidence suggests Cromisol may also influence neuronal pathways by inhibiting the response of sensory C fibers to specific stimuli. This secondary effect modifies exaggerated neuronal reflexes and influences the resting membrane potential within targeted cells, contributing to specific systemic physiological modulation without inducing therapeutic outcomes.

Dosage and Administration Information

Cromisol is administered via distinct routes depending on the target site, reflecting its specialized dosage forms. Its active ingredient, Sodium Cromoglycate, is utilized as an oral solution for systemic mastocytosis, an inhalation solution via nebulizer for respiratory prophylaxis, and topical solutions for both ocular and nasal allergic management.

The medicine functions strictly as a prophylactic agent and is not intended for the relief of acute symptoms. Continuous use is essential, as the full therapeutic effect may take between two to six weeks of regular administration to be realized. The typical maintenance schedule across systemic and inhalation therapies requires administration four times daily (QID) at regular, evenly spaced intervals throughout the day.

For oral administration, the ampule contents, typically 200 mg for adults, must be mixed entirely with a glass of water and consumed one-half hour before meals and at bedtime to ensure proper absorption. Dilution should not occur with liquids such as milk or fruit juice. Official guidance advises that a lower initial dose should be considered for pediatric patients, older adults, and individuals with hepatic or renal impairment. To discontinue therapy, the dosage is generally reduced gradually rather than stopped abruptly, as directed by official labeling.

Recent Clinical Evidence

Research evidence / Overview of studies for Cromisol

Evidence for Use in Allergic Eye Symptoms (Conjunctivitis)

Research exploring how symptoms change over time for allergic eye conditions primarily consists of randomized controlled trials (RCTs). Studies monitored patient-reported outcomes describing discomfort, such as itching and redness. Findings describe patterns observed in some trials showing measured differences compared to placebo. However, when multiple trials are combined in larger analyses, the reported changes were not consistently observed, leading to variability in the overall findings. Limited information exists regarding long-term outcomes or comparative evidence against newer agents evaluated for similar conditions.


Evidence for Prevention of Exercise-Induced Bronchoconstriction

The agent was evaluated in research exploring acute breathing issues, specifically exercise-induced bronchoconstriction (EIB). This research typically used controlled challenge studies where the medicine was applied shortly before a standardized exercise test. The primary outcomes research examined were physiological measures of lung function, such as the maximum percent decrease in FEV1. Data show patterns where measured changes in lung function after exercise were observed, and these patterns differed from the changes observed with a non-medicated intervention. These findings were generally described as consistent across many trials, but results apply only to the immediate, prophylactic setting.


Research for Maintenance Therapy in Chronic Asthma

Research explored the agent's application in the long-term management context, particularly in children with chronic asthma, by using older randomized trials. Studies monitored outcomes reflecting daily functioning, such as the percentage of symptom-free days. The analysis of these studies indicated that the findings were mixed, and pooling the research data did not describe a clear difference from the placebo for symptom-free days. Certainty remains low for this potential application, as evidence quality varies across studies, with sample sizes that were modest and follow-up durations that were limited.


Studies for Systemic Mast Cell Conditions

The agent was evaluated in research exploring conditions characterized by fluctuating manifestations, specifically the gastrointestinal and cutaneous symptoms associated with Systemic Mastocytosis. Research primarily used randomized, placebo-controlled crossover trials. Studies exploring short-term symptom changes described that compared to placebo, the observed populations had measured patterns of change in symptom severity, particularly for gastrointestinal manifestations. Due to the condition's rarity, the total number of participants included remains small, meaning results reflect group patterns, not personal outcomes.


Research Limitations and Populations Studied

Research has explored the agent in both adults and children for allergic eye conditions and EIB. For chronic asthma, studies focused specifically on children. Data for certain groups, such as older adults, remain insufficient. Across all indications, key research limitation frames include the modest sample sizes, lack of comparative evidence for newer treatments, and the fact that long-term effects are not fully established.

Key Studies & References

  1. Label: CROMOLYN SODIUM Oral Solution (Concentrate) - DailyMed (Used for Systemic Mastocytosis indications and general profile)
  2. Label: CROMOLYN SODIUM Ophthalmic Solution - DailyMed (Used for Allergic Eye Symptoms indications)

Frequently Asked Questions (FAQ)

Common questions about Cromisol (FAQ)


Q: How quickly does Cromisol start to work?

A: Cromisol is officially classified as a preventative (prophylactic) agent, meaning it is not intended to provide relief for acute or sudden symptoms. According to regulatory documents, the full therapeutic effect for chronic management is typically realized only after two to six weeks of regular, continuous administration.


Q: Is Cromisol used to treat anxiety or mood problems?

A: The medicine is not indicated for treating anxiety or mood disorders. However, psychiatric symptoms like anxiety, depression, behavior changes, and nervousness have been reported as adverse events in post-marketing experience.


Q: Do the side effects of Cromisol go away over time?

A: Official patient guidance indicates that for certain common adverse effects associated with the oral solution, such as abdominal pain, nausea, and headache, they may be temporary. This may be observed in some instances, particularly if those symptoms overlap with the patient's underlying condition.


Q: Can Cromisol be taken with common dietary supplements or other prescription medications?

A: According to official product information, Cromisol is poorly absorbed into the bloodstream. This typically results in a low potential for widespread systemic drug-to-drug interactions, even with common over-the-counter products, supplements, or other prescription medications.


Q: Can Cromisol affect sleep patterns?

A: Less common adverse events reported include trouble in sleeping (insomnia), dizziness, and drowsiness. These effects relate to nervous system function and are documented in regulatory reports.


Q: Is it true that Cromisol interacts with certain foods or drinks?

A: There are no widely documented systemic food-drug interactions (like the kind associated with grapefruit) for Cromisol. However, the oral solution must be mixed only with water, and official labeling explicitly restricts mixing it with milk, fruit juice, or food because these may interfere with how the medicine works.


Q: What happens if I forget to take a dose of Cromisol?

A: If a dose is missed, official patient information advises taking it as soon as one remembers. If it is almost time for the next scheduled dose, one should skip the missed dose and return to the regular schedule. Official guidance states that extra medicine should not be taken to compensate for a forgotten dose.


Q: Is Cromisol considered a long-term medication?

A: Yes. Cromisol is officially classified as a prophylactic agent. This means it is intended for continuous, regular use as maintenance therapy to prevent the onset or worsening of chronic symptoms, rather than being used only when symptoms occur.


Q: Is Cromisol the generic name or a brand name?

A: Cromisol is the brand name of the medicine. The active ingredient contained within is Sodium Cromoglycate, which is also referred to as Cromolyn sodium, its generic name.


Q: What is the official information regarding driving or operating machinery while on Cromisol?

A: Official prescribing information, particularly for the ophthalmic (eye) solution, warns that transient ocular stinging or blurred vision may occur upon instillation. Regulatory warnings advise that one should refrain from driving or using machinery until normal vision is restored.


Q: Does Cromisol require special monitoring or blood tests?

A: Regulatory documents note that the medicine is eliminated from the body via the kidneys and liver. For patients with impaired renal (kidney) or hepatic (liver) function, regulatory documents indicate a need for close monitoring due to the drug's elimination route.


Q: What is the potential for developing dependence on Cromisol?

A: Regulatory information classifies Cromolyn Sodium as non-addictive and not typically associated with dependence potential. It is not considered a controlled substance.


Q: Is there a Black Box Warning for Cromisol in the US?

A: The official US prescribing information for Cromisol (Sodium Cromoglycate) does not contain a Black Box Warning, which is the Food and Drug Administration's most severe safety caution for certain prescription drugs.


Q: What happens when Cromisol is stopped, and is there information about withdrawal symptoms?

A: Official product information suggests that dosage reduction should be gradual when therapy is discontinued. Symptoms of the condition being treated may recur or worsen if the drug is stopped abruptly or the dosage is reduced below the recommended amount.


Q: What is known about the long-term effects of Cromisol?

A: Studies have examined the long-term effects in animals and found no evidence of carcinogenicity (cancer risk). However, regulatory documents indicate that long-term effects in humans are not fully established due to limited follow-up periods in some clinical trials.


Q: Is it true that Cromisol is only for severe cases?

A: Cromisol is generally approved for the routine prophylactic management of allergic symptoms in most populations. The specific caution regarding use being reserved for severe disease applies only to infants and children under two years of age.


Q: Does Cromisol interact with alcohol?

A: Official patient guidance indicates that the use of the medicine with substances like alcohol should be reviewed with a healthcare professional.

How should Cromisol be stored and disposed of?

Official Storage and Disposal Requirements

Cromisol (Cromolyn Sodium) must be stored under specific conditions to maintain stability, as mandated by regulatory labeling.

Storage Condition Requirement
Temperature Store at Controlled Room Temperature (typically 15 C to 30 C).
Protection Protect from light; the Ophthalmic Solution must not be frozen.
Packaging Keep the Ophthalmic Solution container tightly closed; retain inhalation and oral solution unit-doses in their original foil pouch until use.
Stability Do not use the Inhalation or Oral Solution if it appears discolored or contains a precipitate.
Child Safety Keep out of the reach and sight of children.
Disposal Dispose of unused or expired product according to local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cromisol found in:

A-Z Index: